Syros Pharmaceuticals

SYRS48

Penny Stock

$1.94arrow_drop_down2.02%-$0.04

Penny Stock

SYRS48

$1.94

arrow_drop_down2.02%-$0.04

Penny Stock

Performance History

Key Stats
Open	$1.95
Prev. Close	$1.98
EPS	-4.35
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$53.08M
PE Ratio	-

	LOW	HIGH
Day Range	1.89	2.03
52 Week Range	1.43	8.17

Ratios







EPS	-4.35

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals Inc (SYRS) is a biopharmaceutical company that focuses on developing medicines to control the expression of genes and treat patients with cancer and other diseases. The company's proprietary gene control platform enables it to discover and develop drugs that target gene regulatory regions, known as non-coding DNA, to drive optimal gene expression. By leveraging its platform, Syros aims to uncover novel gene control targets and develop medicines that can modulate gene expression to treat diseases that have been historically challenging to address.

As of the most recent trading session, Syros Pharmaceuticals Inc had a market capitalization of XXX billion. Its PEG ratio, which indicates the stock's valuation relative to its expected growth rate, stands at XXX. This suggests that the company's stock may be valued at a premium compared to its future growth prospects. However, it is important to note that the PEG ratio should be interpreted in conjunction with other financial metrics and industry comparables to gain a comprehensive understanding of a company's valuation.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Nancy A. Simonian M.D.
Headquarters: Cambridge
Employees: 117
Exchange: NASDAQ

Keep an eye on Syros Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Syros Pharmaceuticals 's (SYRS) price per share?

The current price per share for Syros Pharmaceuticals (SYRS) is $1.94. The stock has seen a price change of -$0.04 recently, indicating a -2.02% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Syros Pharmaceuticals (SYRS)?

For Syros Pharmaceuticals (SYRS), the 52-week high is $8.17, which is 321.13% from the current price. The 52-week low is $1.43, the current price is 35.66% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Syros Pharmaceuticals (SYRS) a growth stock?

Syros Pharmaceuticals (SYRS) has shown an average price growth of 0.41% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Syros Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Syros Pharmaceuticals (SYRS) stock price performance year to date (YTD)?

As of the latest data, Syros Pharmaceuticals (SYRS) has a year-to-date price change of -75.26%. Over the past month, the stock has experienced a price change of 11.49%. Over the last three months, the change has been -63.47%. Over the past six months, the figure is -68.86%. Looking at a longer horizon, the five-year price change stands at -98.21%.

help

Is Syros Pharmaceuticals (SYRS) a profitable company?

Syros Pharmaceuticals (SYRS) has a net income of -$164.57M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 77.33% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.84K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $9.94M, although specific revenue growth data is currently not available. The gross profit is $7.68M. Operating income is noted at -$126.5M. Furthermore, the EBITDA is -$116M.

help

What is the market capitalization of Syros Pharmaceuticals (SYRS)?

Syros Pharmaceuticals (SYRS) has a market capitalization of $53.08M. The average daily trading volume is 529.88K, indicating the stock's liquidity and investor engagement.